• Recruiting

NCT04557150: Phase 1: Safety and Pharmacokinetics of Escalating Doses of RO7425781 RRMM Myeloma

Updated: Jun 8

NCT04557150: Phase 1: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)


RG6234

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)


This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. RO7425781 will be administered to participants with r/r MM for whom no standard-of-care treatment exists or who are intolerant to those established therapies. The study consists of two parts: dose-escalation of RO7425781 (Part 1) and a randomized dose expansion of RO7425781 (Part 2).


Sponsor:

Hoffmann-La Roche

 

ClinicalTrials.gov Identifier: NCT04557150


Official Title: An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma


First Posted : September 21, 2020


Click here to see details on ClinicalTrials.gov

 

Drug: RO7425781

Anti-GPRC5D - (RG6234)

 

EHA 2022 Oral Presentations

EHA 2022 - HYBRID - JUNE 9-17 - VIENNA

RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL


Click here to see Abstract details

 

EHA 2022 Oral Presentations

EHA 2022 - HYBRID - JUNE 9-17 - VIENNA

T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA


Click here to see Abstract details

 

Locations

Australia, Victoria

Europe

United Kingdom

France

Italy

Spain

Belgium

Denmark

Asia

Korea, Republic of





Posts Archive